Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Prostatic Neoplasms 4Breast Neoplasms 2Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Ganglioneuroblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × Congresses as Topic × Clear all
NCT00126555 2019-08-30

Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer

National Cancer Institute (NCI)

Phase 2 Completed
23 enrolled 12 charts
Dermatologic

Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡